Cloud Capital Management’s Vaxcyte PCVX Stock Holding History

Cloud Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	–	–	1103
2025 Q3	$0	Buy	+2	New	+$66	﹤0.01%	1388

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cloud Capital Management's PCVX Position: Q4 2025 in Review

Cloud Capital Management sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 2 shares.

Cloud Capital Management first reported a position in PCVX in Q3 2025 and held it in 1 quarter. The position peaked at $0 in Q3 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Cloud Capital Management reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Cloud Capital Management sold 2 Vaxcyte shares in Q4 2025.
Cloud Capital Management first reported a position in Vaxcyte in Q3 2025 and held it in 1 quarter.
Cloud Capital Management's Vaxcyte position peaked at $0 in Q3 2025.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Cloud Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.